Eli Lilly and Company (LLY) Releases Q2 2025 Results

Eli Lilly and Company (NYSE:LLY) is one of the Reddit Stocks with the Highest Upside Potential. On August 7, the company released Q2 2025 results, with revenues increasing 38% to $15.56 billion, thanks to the volume growth from Zepbound and Mounjaro. Furthermore, Eli Lilly and Company (NYSE:LLY) raised the midpoint of its 2025 full-year revenue guidance by $1.5 billion to be between $60 billion – $62 billion. The company expects reported EPS to be between $20.85 – $22.10, and non-GAAP EPS of between $21.75 – $23.00.

Eli Lilly and Company (NYSE:LLY)’s pipeline has been advancing, thanks to positive study results in oncology and cardiometabolic health, such as Mounjaro’s demonstrated cardio-protective effects in patients with type 2 diabetes and heart disease and healthy data for its oral incretin, orforglipron, in obesity. Eli Lilly and Company (NYSE:LLY) also expanded manufacturing capacity in a bid to meet elevated demand and invested in critical R&D initiatives to support its long-term growth. In Q2 2025, R&D expenses rose 23% to $3.34 billion, or 21.4% of revenue. This was because of continued investments in its early and late-stage portfolio.

Impax Asset Management, an investment management company, released its Q2 2025 investor letter. Here is what the fund said:

“Eli Lilly and Company (NYSE:LLY) (Health Care, Pharmaceuticals) boasts an innovative drug portfolio that has the potential to transform the standard of care across several diseases. The stock was weaker in the quarter despite results that were in-line or better than expectations. Shares were under pressure after CVS’ announcement that competitor Novo Nordisk’s Wegovy will now be the preferred GLP-1 drug on their national formulary, which currently represents a mid-single digit percentage of Lilly’s current Zepbound patients.”

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None. This article is originally published at Insider Monkey.